



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Tirofiban hydrochloride monohydrate

Cat. No.:	HY-17369
CAS No.:	150915-40-5
Molecular Formula:	C ₂₂ H ₃₉ ClN ₂ O ₆ S
Molecular Weight:	495
Target:	Integrin
Pathway:	Cytoskeleton
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (202.02 mM; Need ultrasonic)					
	Preparing Stock Solutions	<div>Solvent</div> <div>Concentration</div>	Mass	1 mg	5 mg	10 mg
		1 mM		2.0202 mL	10.1010 mL	20.2020 mL
		5 mM		0.4040 mL	2.0202 mL	4.0404 mL
		10 mM		0.2020 mL	1.0101 mL	2.0202 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.5 mg/mL (5.05 mM); Suspended solution; Need ultrasonic					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (5.05 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (5.05 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	Tirofiban (L700462) hydrochloride monohydrate is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban hydrochloride monohydrate induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban hydrochloride monohydrate can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area ^{[1][2][3]} .
IC ₅₀ & Target	Gp IIb/IIIa Receptor ^[1]
In Vitro	Tirofiban hydrochloride monohydrate (0.25, 1, 3 μg/mL; 72 hours) increases proliferation of HAEC cells ^[1] .

Tirofiban hydrochloride monohydrate (24 hours) closes the scratch of HUVECs migration within 18 hours^[1].

Tirofiban hydrochloride monohydrate (0.25, 1 µg/mL; 1 hour) induces production of VEGF after 30 minutes which can stimulates proliferation of endothelial cells^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:	HAEC cells
Concentration:	0.25, 1, 3 µg/mL
Incubation Time:	72 hours
Result:	Increased proliferation of HAEC cells.

Cell Migration Assay^[1]

Cell Line:	HUVEC cells
Concentration:	
Incubation Time:	24 hours
Result:	Stimulated the migratory capacity of endothelial cells.

Western Blot Analysis^[1]

Cell Line:	HAEC cells
Concentration:	0.05, 0.12, 0.25, 1 µg/mL
Incubation Time:	1 hour
Result:	Induced production of VEGF which stimulated proliferation of endothelial cells.

In Vivo

Tirofiban hydrochloride monohydrate (60 µg/kg; i.v.; once) shows activity of increasing contraction force, ventricular compliance, and improving heart function by increasing HR, LVESP, dp/dtmax, and reducing LVEDP^[2].

Tirofiban hydrochloride monohydrate (60 µg/kg; i.v.; once) enhances eNOS activity, decreases iNOS activity and reduces area of no-reflow after reperfusion following AMI^[2]. Tirofiban hydrochloride monohydrate (50 µg/per; irrigate; once) shows anticoagulant effect with patency rates of 59% at 24 hours after microvascular anastomosis in the crush model^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague-Dawley rats (10 to 15-week-age; 270-330 g) ^[2] .
Dosage:	60 µg/kg
Administration:	Intravenous injection; once.
Result:	Increased contraction force, ventricular compliance, and improved heart function. Reduced the size of no-reflow and infarct.
Animal Model:	Sprague-Dawley rats (350-400 g; crush injury model) ^[3]
Dosage:	50 µg/per (50 µg/mL, 1 mL for each)
Administration:	Irrigate 1 mL within the vessel lumen (before placement of the last suture); once.

Result:	Showned anticoagulant effect with patency rates of 59%.
---------	---

REFERENCES

- [1]. Giordano A, et al. Tirofiban induces VEGF production and stimulates migration and proliferation of endothelial cells. *Vascul Pharmacol*. 2014 May-Jun;61(2-3):63-71.
- [2]. Liu X, et al. Effects of tirofiban on the reperfusion-related no-reflow in rats with acute myocardial infarction. *J Geriatr Cardiol*. 2013 Mar;10(1):52-8.
- [3]. Yates YJ, et al. The effect of tirofiban on microvascular thrombosis: crush model. *Plast Reconstr Surg*. 2005 Jul;116(1):205-8
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA